| アブストラクト | BACKGROUND AND OBJECTIVES: Although thromboembolic events (TEEs) have been reported with the use of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), their association remains largely unknown. In this study, we aimed to provide a comprehensive review of TEEs associated with EGFR-TKIs. METHODS: We collected EGFR-TKIs (gefitinib, erlotinib, afatinib, and osimertinib) adverse reaction reports from 2015 Q1 to 2023 Q1 from the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database. Disproportionality analysis was conducted to identify thromboembolic adverse events associated with EGFR-TKIs by comparing them with the overall FAERS database according to the reporting odds ratio (ROR). Associated factors were explored using univariate logistic regression. RESULTS: We identified 1068 reports of TEEs associated with EGFR-TKIs (1.24% accounts for all TEEs). Affected patients were females (49.72%) and those older than 65 years (41.20%). The reported TEE case fatality was 30.24%. The median time to onset (TTO) of all cases was 39 days [interquartile range (IQR) 11-161], and the median TTO of fatalities [31 days (IQR 10-116)] was significantly shorter than that of non-fatal cases [46 days (IQR 12-186)]. CONCLUSION: This study yielded three key findings. Firstly, EGFR-TKIs seem to exhibit prothrombotic effects, elevating the risk of TEEs. Secondly, the clinical outcomes of TEEs associated with EGFR-TKIs were poor. Thirdly, most TEEs occurred within the initial 3 months, and fatal cases occurred earlier than non-fatal cases. |
|---|
| ジャーナル名 | Clinical drug investigation |
|---|
| 投稿日 | 2024/2/20 |
|---|
| 投稿者 | Yang, Xiongwen; Yang, Bo; Li, Dan; Pan, Wei; Tong, Qin; Wang, Lili; Chen, Danjun; Fu, Chengxiao |
|---|
| 組織名 | Department of Pharmacy, The First Affiliated Hospital, Hengyang Medical School,;University of South China, Hengyang, 421001, Hunan, People's Republic of China.;Institute of Pharmacy and Pharmacology, College of Basic Medical Science,;Hengyang Medical School, University of South China, Hengyang, 421200, Hunan,;People's Republic of China.;Department of Oncology, The First Affiliated Hospital, Hengyang Medical School,;paulfcx@126.com.;People's Republic of China. paulfcx@126.com.;Clinical Pharmacology Research Center, The First Affiliated Hospital, Hengyang;Medical School, University of South China, Hengyang, 421001, Hunan, People's;Republic of China. paulfcx@126.com. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/38376794/ |
|---|
